FP18-adjuvanted OprF also enhanced the productionof anti-OprF antibodies and stimulated IFNγ and TNF in CD4+ T cells, suggesting a Th1-skewed cellular immune response.These adjuvants have promise for accelerating the development of effectivevaccines against P. aeruginosa andother infectious diseases. This evidence concerns the gene CD4 and infectious disease.